It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Inflammation is a part of the body’s intricate biological reaction to noxious stimuli and defensive reactions. So, the aim of this investigation was to study the anti-inflammatory activity of exopolysaccharide (EPSSM) using carrageenan-induced paw edema in rats. A halophilic bacterial strain was isolated from marine sediments in the Red Sea in Egypt. The isolate has been visually and physiologically recognized, as well as by analyzing its 16S rRNA gene, which confirms Kocuria sp. clone Asker4. This particular isolate can be referenced using the accession number OL798051.1. EPSSM was subjected to purification and fractionation by a DEAE-cellulose column. Preliminary chemical analysis of EPSSM indicated that the monosaccharides were fructose, glucuronic acid, and xylose, with 2.0, 0.5, and 1.0, respectively. The antioxidant potential of EPSSM was investigated, and it was discovered that the level of activity increased independently of the concentrations, reaching a maximum threshold of 94.13% at 100 µg/mL of EPSSM for 120 min. Also, EPSSM at 50 mg/kg orally produced a significant anti-inflammatory effect on the carrageenan model at 2, 3, and 4 intervals. The EPSSM intervention resulted in reductions in the levels of catalase and superoxide dismutase enzymes, as well as a decrease in glutathione. Furthermore, the levels of nitric oxide, lipid peroxidation, and reactive oxygen species resulting from carrageenan-induced edema showed a significant reduction subsequent to the administration of EPSSM. Moreover, the findings indicated that the protein expression levels of cyclooxygenase-2 and interleukin-6 were reduced following treatment with EPSSM, resulting in a reduction of paw edema.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Research Centre, Microbial Biotechnology Department, Cairo, Egypt (GRID:grid.419725.c) (ISNI:0000 0001 2151 8157)
2 National Organization for Drug Control and Research (NODCAR)/Egyptian Drug Authority (EDA), Department of Biochemistry, Cairo, Egypt (GRID:grid.419698.b)
3 National Organization for Drug Control and Research (NODCAR), Molecular Drug Evaluation Department, Cairo, Egypt (GRID:grid.419698.b)
4 Cairo University, Senior research associate at 57357 hospital Master of life science informatics at Bonn university, Bachelor of pharmaceutical sciences, Cairo, Egypt (GRID:grid.7776.1) (ISNI:0000 0004 0639 9286)
5 Children’s Cancer Hospital Egypt 57357, Proteomics and Metabolomics Research Program, Basic Research Unit, Research Department, Cairo, Egypt (GRID:grid.428154.e) (ISNI:0000 0004 0474 308X); Suez Canal University, Department of Physiology, Faculty of Veterinary Medicine, Ismailia, Egypt (GRID:grid.33003.33) (ISNI:0000 0000 9889 5690)
6 National Research Center, Microbial Genetics Department, Cairo, Egypt (GRID:grid.419725.c) (ISNI:0000 0001 2151 8157)
7 Al-Azhar University, Microbiology Department, Faculty of Science, Cairo, Egypt (GRID:grid.411303.4) (ISNI:0000 0001 2155 6022)